BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
November 14, 2023 07:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
November 08, 2023 16:11 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
November 01, 2023 17:04 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
September 06, 2023 07:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
September 05, 2023 07:15 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
August 09, 2023 16:05 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
August 02, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
July 24, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
June 20, 2023 17:14 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Cancer Genetics Expert Dr. Kelly Bolton Appointed to GoodCell’s Scientific Advisory Board
July 25, 2022 07:30 ET
|
GoodCell
Waltham, MA, July 25, 2022 (GLOBE NEWSWIRE) -- GoodCell, a Harvard Stem Cell Institute company, today appointed Kelly Bolton M.D., Ph.D., M.Phil., to its scientific advisory board. With a...